Goldstein v. Denner

Court of Chancery of Delaware·Decided June 2, 2022·No. C.A. No. 2020-1061-JTL·Published

Opinion

EFiled: Jun 02 2022 10:29AM EDT Transaction ID 67683224 Case No. 2020-1061-JTL

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

STEWART N. GOLDSTEIN, individually and ) on behalf of all others similarly situated, )

)

Plaintiff, )

)

v. ) C.A. No. 2020-1061-JTL )

ALEXANDER J. DENNER, JOHN G. COX, ) ANNA PROTOPAPAS, BRIAN S. POSNER, ) LOUIS J. PAGLIA, GENO J. GERMANO, ) JOHN T. GREENE, ANDREA DIFABIO, ) SARISSA CAPITAL MANAGEMENT, L.P., ) SARISSA CAPITAL DOMESTIC FUND LP, ) SARISSA CAPITAL OFFSHORE MASTER ) FUND LP, and SARISSA CAPITAL ) MANAGEMENT GP LLC, )

)

Defendants. )

MEMORANDUM OPINION ADDRESSING MOTION TO DISMISS COUNTS III AND IV

Date Submitted: March 4, 2022 Date Decided: June 2, 2022

Kevin H. Davenport, John G. Day, PRICKETT, JONES & ELLIOT P.A., Wilmington, Delaware; R. Bruce McNew, COOCH & TAYLOR P.A., Wilmington, Delaware; Randall J. Baron, David T. Wissbroecker, ROBBINS GELLER RUDMAN & DOWD LLP, San Diego, California; Christopher H. Lyons, ROBBINS GELLER RUDMAN & DOWD LLP, Nashville, Tennessee; Brett Middleton, JOHNSON FISTEL, LLP, New York, New York; Attorneys for Plaintiff.

Matthew D. Stachel, PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP, Wilmington, Delaware; Daniel J. Kramer, Geoffrey R. Chepiga, Daniel J. Juceam, PAUL, WEISS, RIFKIND, WHARTON & GARRISON LLP, New York, New York; Attorneys for Defendants John G. Cox, Anna Protopapas, Brian S. Posner, Louis J. Paglia, Geno J. Germano, John T. Greene, and Andrea DiFabio.

Stephen E. Jenkins, Richard D. Heins, ASHBY & GEDDES, P.A., Wilmington, Delaware; Tariq Mundiya, Sameer Advani, Richard Li, M. Annie Houghton-Larsen, WILLKIE FARR & GALLAGHER LLP, New York, New York; Attorneys for Defendants Alexander J. Denner, Sarissa Capital Management LP, Sarissa Capital Domestic Fund LP, Sarissa Capital Offshore Master Fund LP, and Sarissa Capital Management GP LLC.

LASTER, V.C.

In 2017, defendant Alexander J. Denner was a member of the board of directors (the

“Board”) of Bioverativ, Inc. (the “Company”), a publicly traded biotechnology firm.

Denner was also the founder and controlling principal of an activist hedge fund, consisting

of an interconnected group of entities affiliated with Sarissa Capital Management, L.P.

(collectively, “Sarissa”).

In May 2017, Sanofi S.A. approached Denner and another Company director,

defendant Brian S. Posner. Sanofi expressed interest in buying the Company for around

$90 per share. On the day of Sanofi’s approach, the Company’s common stock closed at

$54.86 per share. Sanofi’s proposed price represented a premium of 64.1% over the market

price.

The two directors demurred. The complaint supports a reasonable inference that

neither of them disclosed Sanofi’s approach to the Board.

Instead, Denner caused Sarissa to buy more than a million shares of Company

common stock, octupling his holdings. The purchases violated the Company’s insider

trading policy. Denner did not disclose the purchases to the Board.

Denner stood to make massive profits if Sanofi acquired the Company, but Section

16(b) of the Securities Exchange Act of 1934 loomed as an impediment. That statute

requires that an insider disgorge short-swing profits from any sale that takes place less than

six months after the purchase. The solution was to delay any engagement with Sanofi so

that the sale would take place after the short-swing period closed.

That is exactly what Denner and Posner did. When Sanofi approached Denner and

Posner about a transaction in June 2017 and again in September 2017, they told Sanofi that

the Company was not for sale. By October 2017, however, the short-swing period was

about to expire. This time when Sanofi came calling, Denner proposed a single-bidder

process. Denner acted unilaterally to put the Company in play. The Board knew nothing

about Sanofi’s inquiries.

Several weeks later, in late November 2017, Sanofi offered to acquire the Company

for $98.50 per share. This was the first time that the Board learned about Sanofi’s interest.

The Company’s management team and its financial advisors had valued the

Company at more than $150 per share using the projections in the Company’s long-range

plan. After receiving Sanofi’s offer, the Board asked for a higher bid, and Sanofi increased

its offer to $101.50. At that point, the Board countered at $105 per share, almost one-third

below the Company’s standalone valuation under its long-range plan. Sanofi accepted the

Board’s counter.

The Board approved an agreement and plan of merger with Sanofi (the

“Transaction”). In March 2018, the Transaction closed. Sarissa’s purchases of Company

common stock generated a profit of $49.7 million.

In this lawsuit, the plaintiff asserts that the members of the Board and three of the

Company’s officers breached their fiduciary duties during the sale process (the “Sale

Process Claims”). The plaintiff also asserts that the same defendants breached their

fiduciary duty of disclosure when providing stockholders with information about the

Transaction. The defendants moved to dismiss those theories as failing to state claims on

which relief can be granted. The court previously issued a decision that largely denied that

motion. Goldstein v. Denner (Sale Process Decision), 2022 WL 1671006, at *1 (Del. Ch.

May 26, 2022).

The plaintiff also asserts a claim against Denner for breach of fiduciary duty under

Brophy v. Cities Service Co., 70 A.2d 5 (Del. Ch. 1949). And the plaintiff asserts a claim

against Sarissa for aiding and abetting Denner’s breaches of fiduciary duty. In substance,

those claims assert that Denner and Sarissa engaged in insider trading (the “Insider Trading

Claims”).

The defendants moved to dismiss the Insider Trading Claims on two grounds. They

argued that the plaintiff had failed to state reasonably conceivable claims, and they asserted

that the plaintiff lost standing to pursue the Insider Trading Claims when the Transaction

closed. The Sale Process Decision deferred consideration of those issues.

This decision finds that the plaintiff has stated a reasonably conceivable claim that

Denner breached his duty of loyalty by causing Sarissa to purchase shares of Company

common stock after Denner learned material, non-public information about Sanofi’s

interest in acquiring the Company. In moving to dismiss, the defendants argued that

Sanofi’s confidential expression of interest in acquiring the Company at more than a 64%

premium over the market price did not constitute material, non-public information. They

also argued that the court could not infer at the pleading stage that Denner caused Sarissa

to buy shares on the basis of Sanofi’s expression of interest. At the pleading stage, it is

reasonable to infer that the information was material and that Denner acted on it.

This decision finds that the plaintiff has stated a reasonably conceivable claim

against Sarissa for aiding and abetting Denner’s breach of the duty of loyalty. In moving

to dismiss that claim, the defendants did not dispute any element except for the existence

of an underlying breach of duty. Because it is reasonably conceivable that Denner breached

his duty of loyalty, it is reasonably conceivable that Sarissa aided and abetted the breach

by carrying out Denner’s insider trading.

A far stronger argument is the defendants’ contention that the plaintiff lost standing

to pursue the Insider Trading Claims when the Transaction closed. The defendants observe

that the Insider Trading Claims rest on the theory that Denner misused the Company’s

confidential information in a manner that constitutes a breach of the duty of loyalty under

Brophy. They correctly point out that a Brophy claim is a derivative claim. See Latesco,

L.P. v. Wayport, Inc., 2009 WL 2246793, at *6 (Del. Ch. July 24, 2009) (“A Brophy claim

is fundamentally derivative in nature, because it arises out of the misuse of corporate

property—that is, confidential information—by a fiduciary of the corporation, for the

benefit of the fiduciary and to the detriment of the corporation.”). They further point out

Free access — add to your briefcase to read the full text and ask questions with AI

Goldstein v. Denner, (Del. Ct. App. 2022).

Goldstein v. Denner (Goldstein v. Denner) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

TSC Industries, Inc. v. Northway, Inc.
426 U.S. 438 (Supreme Court, 1976)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Clarence v. Watson v. Woodrow C. Button
235 F.2d 235 (Ninth Circuit, 1956)
Atkinson v. Marquart
541 P.2d 556 (Arizona Supreme Court, 1975)
Parnes v. Bally Entertainment Corp.
722 A.2d 1243 (Supreme Court of Delaware, 1999)
Field v. Allyn
467 A.2d 1274 (Supreme Court of Delaware, 1983)
Feldman v. Cutaia
951 A.2d 727 (Supreme Court of Delaware, 2008)
Miller v. Steinbach
268 F. Supp. 255 (S.D. New York, 1967)
May v. Midwest Refining Co.
121 F.2d 431 (First Circuit, 1941)
Lewis v. Anderson
477 A.2d 1040 (Supreme Court of Delaware, 1984)
In RE ORACLE CORP. DERIVATIVE LITIGATION v. Oracle Corp.
872 A.2d 960 (Supreme Court of Delaware, 2005)
Malpiede v. Townson
780 A.2d 1075 (Supreme Court of Delaware, 2001)
Backus v. Finkelstein
23 F.2d 357 (D. Minnesota, 1927)
In Re Oracle Corp.
867 A.2d 904 (Court of Chancery of Delaware, 2004)
Kirk v. First Nat. Bank of Columbus
439 F. Supp. 1141 (M.D. Georgia, 1977)
DeHaas v. Empire Petroleum Company
300 F. Supp. 834 (D. Colorado, 1969)
Holi-Rest, Inc. v. Treloar
217 N.W.2d 517 (Supreme Court of Iowa, 1974)
Gerstle v. Gamble-Skogmo, Inc.
298 F. Supp. 66 (E.D. New York, 1969)